167 related articles for article (PubMed ID: 32435367)
1. Development of Pyrazolo[3,4-
Greco C; Taresco V; Pearce AK; Vasey CE; Smith S; Rahman R; Alexander C; Cavanagh RJ; Musumeci F; Schenone S
ACS Med Chem Lett; 2020 May; 11(5):657-663. PubMed ID: 32435367
[TBL] [Abstract][Full Text] [Related]
2. Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
Nešović M; Divac Rankov A; Podolski-Renić A; Nikolić I; Tasić G; Mancini A; Schenone S; Pešić M; Dinić J
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545852
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolo[3,4-
Kostić A; Jovanović Stojanov S; Podolski-Renić A; Nešović M; Dragoj M; Nikolić I; Tasić G; Schenone S; Pešić M; Dinić J
Brain Sci; 2021 Jun; 11(7):. PubMed ID: 34209342
[TBL] [Abstract][Full Text] [Related]
4. Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4-
Poggialini F; Vagaggini C; Brai A; Pasqualini C; Crespan E; Maga G; Perini C; Cabella N; Botta L; Musumeci F; Frosini M; Schenone S; Dreassi E
Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839775
[TBL] [Abstract][Full Text] [Related]
5. Identification and Biological Characterization of the Pyrazolo[3,4-
Contadini C; Cirotti C; Carbone A; Norouzi M; Cianciusi A; Crespan E; Perini C; Maga G; Barilà D; Musumeci F; Schenone S
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513870
[TBL] [Abstract][Full Text] [Related]
6. Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells.
Monteleone L; Marengo B; Musumeci F; Grossi G; Carbone A; Valenti GE; Domenicotti C; Schenone S
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890294
[TBL] [Abstract][Full Text] [Related]
7. Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment.
Vagaggini C; Petroni D; D'Agostino I; Poggialini F; Cavallini C; Cianciusi A; Salis A; D'Antona L; Francesconi V; Manetti F; Damonte G; Musumeci F; Menichetti L; Dreassi E; Carbone A; Schenone S
Drug Dev Res; 2024 Feb; 85(1):e22158. PubMed ID: 38349262
[TBL] [Abstract][Full Text] [Related]
8. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
[TBL] [Abstract][Full Text] [Related]
9. A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-
Fallacara AL; Zamperini C; Podolski-Renić A; Dinić J; Stanković T; Stepanović M; Mancini A; Rango E; Iovenitti G; Molinari A; Bugli F; Sanguinetti M; Torelli R; Martini M; Maccari L; Valoti M; Dreassi E; Botta M; Pešić M; Schenone S
Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31248184
[TBL] [Abstract][Full Text] [Related]
10. Autophagy Inhibition Enhances Anti-Glioblastoma Effects of Pyrazolo[3,4-
Jovanović Stojanov S; Kostić A; Ljujić M; Lupšić E; Schenone S; Pešić M; Dinić J
Life (Basel); 2022 Sep; 12(10):. PubMed ID: 36294938
[TBL] [Abstract][Full Text] [Related]
11. SRC family kinase inhibition through a new pyrazolo[3,4-d]pyrimidine derivative as a feasible approach for glioblastoma treatment.
Ceccherini E; Indovina P; Zamperini C; Dreassi E; Casini N; Cutaia O; Forte IM; Pentimalli F; Esposito L; Polito MS; Schenone S; Botta M; Giordano A
J Cell Biochem; 2015 May; 116(5):856-63. PubMed ID: 25521525
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
13. A Pyrazolo[3,4-
Laurenzana I; Caivano A; La Rocca F; Trino S; De Luca L; D'Alessio F; Schenone S; Falco G; Botta M; Del Vecchio L; Musto P
Front Pharmacol; 2016; 7():416. PubMed ID: 27872592
[TBL] [Abstract][Full Text] [Related]
14. Discovery of pyrazolopyrimidines that selectively inhibit CSF-1R kinase by iterative design, synthesis and screening against glioblastoma cells.
Baillache DJ; Valero T; Lorente-Macías Á; Bennett DJ; Elliott RJR; Carragher NO; Unciti-Broceta A
RSC Med Chem; 2023 Dec; 14(12):2611-2624. PubMed ID: 38099057
[TBL] [Abstract][Full Text] [Related]
15. AuNP Pyrazolo[3,4-
Molinari A; Iovenitti G; Mancini A; Gravina GL; Chebbi M; Caruana M; Vignaroli G; Orofino F; Rango E; Angelucci A; Dreassi E; Schenone S; Botta M
ACS Med Chem Lett; 2020 May; 11(5):664-670. PubMed ID: 32435368
[TBL] [Abstract][Full Text] [Related]
16. A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme.
Nehoff H; Parayath NN; McConnell MJ; Taurin S; Greish K
Oncotarget; 2015 Nov; 6(35):37948-64. PubMed ID: 26517812
[TBL] [Abstract][Full Text] [Related]
17. The SGK1 Kinase Inhibitor SI113 Sensitizes Theranostic Effects of the 64CuCl2 in Human Glioblastoma Multiforme Cells.
Catalogna G; Talarico C; Dattilo V; Gangemi V; Calabria F; D'Antona L; Schenone S; Musumeci F; Bianco C; Perrotti N; Amato R; Cascini GL
Cell Physiol Biochem; 2017; 43(1):108-119. PubMed ID: 28848088
[TBL] [Abstract][Full Text] [Related]
18. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells.
Matteoni S; Abbruzzese C; Matarrese P; De Luca G; Mileo AM; Miccadei S; Schenone S; Musumeci F; Haas TL; Sette G; Carapella CM; Amato R; Perrotti N; Signore M; Paggi MG
J Exp Clin Cancer Res; 2019 May; 38(1):202. PubMed ID: 31101126
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
20. Illuminating the Dark: Highly Selective Inhibition of Serine/Threonine Kinase 17A with Pyrazolo[1,5-
Kurz CG; Preuss F; Tjaden A; Cusack M; Amrhein JA; Chatterjee D; Mathea S; Berger LM; Berger BT; Krämer A; Weller M; Weiss T; Müller S; Knapp S; Hanke T
J Med Chem; 2022 Jun; 65(11):7799-7817. PubMed ID: 35608370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
